 In April 1989, the FDA investigated 11 manufacturers for irregularities; and later brought that number up to 13.Dozens of drugs were eventually suspended or recalled by manufacturers.In the early 1990s, the U.S. Securities and Exchange Commission filed securities fraud charges against the Bolar Pharmaceutical Company, a major generic manufacturer based in Long Island, New York.